Systems Medicine's Cancer Drug Found Effective in Preclinical Study
Posted on: Wednesday, 16 April 2008, 12:00 CDT
Systems Medicine, a wholly owned subsidiary of Cell Therapeutics, has presented data from a preclinical study demonstrating that the company's experimental drug candidate, brostallicin, killed colon and ovarian cancer cells regardless of their p53 status.
The study suggests that, while brostallicin is more effective in cells with normal p53 status, cells with abnormal or missing p53 are also killed when treated. P53 is a protein that regulates the cell cycle and acts as a tumor suppressor.
The study examined brostallicin's effect on cell viability, cell cycle modulation, and the initiation of cell death in cancer cell models with either normal (also referred to as wild-type) or abnormal (mutated or absent) p53 tumor suppressor. These results were supported through tests in animal models, where brostallicin demonstrated a statistically significant effect on suppressing tumor growth.
Jeffrey Jacob, CEO of Systems Medicine, said: "The results of this study support the further clinical development of brostallicin. They also provide deeper insight into brostallicin's context of vulnerability concerning different types of p53 protein, and where it is most effective."
Source: Datamonitor
Related Articles
- New Notre Dame Study Provides Insights Into The Molecular Basis Of Tumor Cell Behavior
- Advalytix Announces Study of Single Circulating Tumor Cells With the M. D. Anderson Cancer Center
- Immunicon Corporation Announces Independent Studies to Be Presented at 2007 San Antonio Breast Cancer Symposium That Confirm Utility of the CellSearch(TM) Circulating Tumor Cell Kit
- Biocept Announces Study to Isolate Circulating Tumor Cells From Blood
- Circulating Tumor Cells Help Treatment
- Omega-6 Fatty Acids Cause Prostate Tumor Cell Growth in Culture
- Unique Interplay Between Tumor and Blood Vessel Cells Promotes Angiogenesis and Tumor Growth
- HAMLET Kills Tumor Cells By Apoptosis: Structure, Cellular Mechanisms, and Therapy1,2
- Immunicon Corporation Announces Presentation of Data on Circulating Tumor Cells in 'Non-Measurable' Metastatic Breast Cancer at the 2005 American Association of Clinical Oncology (ASCO) Annual Meeting
- Cancer Therapy; Salvinal has antimitotic activity in drug-resistant human tumor cells
 |
 |
User Comments (0)
RSS Feeds